Effect of recombinant Lactobacillus casei expressing interleukin-10 in dextran sulfate sodium-induced colitis mice

Journal of Digestive Diseases

Volumn 14, Issue 2, 2013, Pages 76-83

  Qiu, Zhi Bing ^a   Chen, Jian ^a   Chen, Jia Jie ^a   Rong, Lan ^a   Ding, Wei Qun ^a   Yang, Hai Jing ^a   Zhong, Liang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Colitis; Cytokine; Dextran sulfate; Inflammatory bowel disease; Interleukin 10; Lactobacillus casei

Indexed keywords

DEXTRAN SULFATE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; COLITIS; COLON; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY SCORE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; HISTOPATHOLOGY; LACTOBACILLUS CASEI; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLON; DEXTRAN SULFATE; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-10; LACTOBACILLUS CASEI; MESALAMINE; MICE; MICE, INBRED BALB C; NF-KAPPA B; PPAR GAMMA; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA;

EID: 84873048239     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12006     Document Type: Article

References (22)

1. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633.
2. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 2005; 21: 426-430.
3. Jones JL, Foxx-Orenstein AE. The role of probiotics in inflammatory bowel disease. Dig Dis Sci 2007; 52: 607-611.
4. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008; 180: 5771-5777.
5. Nouri-Aria KT, Wachholz PA, Francis JN etal. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172: 3252-3259.
6. Enrique E, Pineda F, Malek T etal. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005; 116: 1073-1079.
7. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 2007; 119: 952-959.
8. Qiu ZB, Zhong L, Chen JJ, Rong L, Chen J. Construction of a recombinant lactobacillus strain expressing IL-10. Fudan Univ J Med Sci 2011; 38: 163-167 (in Chinese).
9. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
10. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
11. Rutledge RG, Côté C. Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res 2003; 31: e93.
12. Gionchetti P, Rizzello F, Helwig U etal. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209.
13. Cui HH, Chen CL, Wang JD etal. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10: 1521-1525.
14. Tilg H, van Montfrans C, van den Ende A etal. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 2002; 50: 191-195.
15. Chung YW, Choi JH, Oh TY, Eun CS, Han DS. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin Exp Immunol 2008; 151: 182-189.
16. Fedorak RN, Gangl A, Elson CO etal; The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000; 119: 1473-1482.
17. Kampitak T, Suwanpimolkul G, Browne S, Suankratay C. Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature. Infection 2011; 39: 65-71.
18. Weyand CM, Younge BR, Goronzy JJ. IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 2011; 23: 43-49.
19. De Vry CG, Prasad S, Komuves L etal. Non-viral delivery of nuclear factor-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2007; 56: 524-533.
20. Sugawara K, Olson TS, Moskaluk CA etal. Linkage to peroxisome proliferator-activated receptor-γ in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 2005; 128: 351-360.
21. Takedatsu H, Taylor KD, Mei L etal. Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-κB activation. Gut 2009; 58: 60-67.
22. Dubuquoy L, Jansson EA, Deeb S etal. Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis. Gastroenterology 2003; 124: 1265-1276.